ImmuRx
Lebanon, New Hampshire, United States
About ImmuRx
ImmuRx, Inc. develops adjuvant platforms for the treatment of cancers and infectious diseases. The company’s product includes CD40 compound, an antibody. Its approach reduces solid tumor mass, enhances survival times in cutaneous and hematapoietic tumor models, and protects against viral and bacterial infections in various animal models. The company was incorporated in 2006 and is based in Lebanon, New Hampshire.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $763.4K
- Last round: Series Unknown (Jun 2009)
- Website: immurx.com
- Phone: 4144335390
Industries & Categories
Biotechnology, Developer Platform, Health Diagnostics
Canonical: https://fsome.com/organization/immurx-2463117 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.